Successful Crizotinib-targeted Therapy of Pediatric Unresectable ERC1::ALK Fusion Sarcoma.

Authors :: Wood ML
Fanburg-Smith JC
Brian JM
White JC
Powell JL
Freiberg AS
Source :: Journal of pediatric hematology/oncology [J Pediatr Hematol Oncol] 2024 Mar 01; Vol. 46 (2), pp. e184-e187. Date of Electronic Publication: 2023 Dec 15.
Publication Year :: 2024
Abstract: Anaplastic lymphoma kinase ( ALK )-fusion sarcomas are rare part of the emerging theoretically targetable tyrosine kinase RAS::MAPK pathway fusion myopericytic-ovoid sarcomas. We report our clinicopathologic and treatment experience with an ALK fusion sarcoma. A novel ELKS/RAB6-interacting/CAST family member 1 - unaligned ALK fusion infiltrative nonmetastatic low-grade sarcoma of the right hand of a 15-month-old male was treated with crizotinib, an ALK tyrosine kinase inhibitor as oral monotherapy, inducing complete radiographic and clinical resolution by 10 months and sustained response now over 12 months after elective discontinuation. Crizotinib can successfully be used to treat unresectable novel ALK fusion sarcomas.<br />Competing Interests: The authors declare no conflict of interest.<br /> (Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc.)

Subjects :: Humans
Male
Child
Infant
Crizotinib therapeutic use
Anaplastic Lymphoma Kinase genetics
Protein Kinase Inhibitors therapeutic use
Protein Kinase Inhibitors pharmacology
Protein-Tyrosine Kinases therapeutic use
Sarcoma drug therapy
Sarcoma genetics
Soft Tissue Neoplasms drug therapy
Lung Neoplasms pathology

Full Text Access

Tools